This is the authors' abstract. We don't add key points for this paper.
Background and Aims: A few clinical studies have suggested that low doses of anti-angiogenic molecules might enhance the therapeutic effects of anti-PD1 in HCC and may improve their tolerance. Here, we present case reports of patients treated with low-dose regorafenib combined with nivolumab after the failure of at least two lines of oral chemotherapy.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Merabet et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: